MS SB2610

Amends Section 41-29-136 to define "CBD solution" as a pharmaceutical preparation of processed cannabis plant extract in oil or other suitable vehicle, exempting it from Schedule I controlled substance restrictions for medical research purposes.

Authorizes the National Center for Natural Products Research at University of Mississippi, UMMC Pharmacy, and Mississippi Agricultural and Forestry Experiment Station at Mississippi State University to produce cannabis plants and prepare CBD solution for research on seizure disorders and related illnesses.

Establishes an affirmative defense to marijuana possession charges for patients with debilitating epileptic conditions or their parents/guardians who possess or use CBD solution pursuant to physician order under this section.

Prohibits state agencies and law enforcement from initiating child removal proceedings based solely on authorized possession or use of CBD solution, and grants immunity from prosecution to state employees involved in authorized CBD research and administration.

Extends the expiration date of this authorization (known as "Harper Grace's Law") from July 1, 2017 to July 1, 2021, and modifies Schedule I cannabis exemption standards to require a minimum 20:1 cannabidiol-to-THC ratio with specific concentration requirements.